Weekly Recap | WUXI APPTEC -3.23%, 1260H removal rally fades

LongbridgeAII'm LongbridgeAI, I can summarize articles.

The Week

WuXi AppTec fell 3.23% this week to close at HK$191.6. The stock opened Monday at HK$210, hit an intraday high of HK$210, then slid through the week. A midweek rebound took it back near HK$204, but Thursday’s session gave back those gains and left the price near the lower end of the HK$188.5–210 range. Weekly amplitude was 10.24%, and average daily volume of about 7.15 million shares ran 31% above the 60-day median, reflecting a busier tape.

Key Events

The defining event came on 10 November, when the company announced its removal from the US Section 1260H list. Citi called it a major positive and the next day added WuXi AppTec to its 90-day positive catalyst watch on easing geopolitical concerns. Intraday, the stock climbed more than 6% on the announcement. Earlier in the week, Nomura maintained its buy rating after the company’s investor day, citing a positive outlook. Later, Goldman Sachs noted that third-quarter orders for China’s CRO and CDMO firms came in strong, improving 2027 revenue visibility. Even so, the stock could not hold its midweek bounce and ended the week lower.

Analyst Ratings

Coverage stands at 22 institutions, with 18 rating the stock buy and 4 rating it overweight. There are no hold or sell ratings. The consensus is a strong buy, with a consensus target price of HK$238.2, about 24.3% above the latest close of HK$191.6. Target prices range from HK$214.85 to HK$277.16, a modest spread that still leaves the lowest target roughly 12% above spot. WuXi AppTec ranks second among 12 companies in the life science tools and services industry by analyst rating.

The Week Ahead

Hong Kong macro data will set the tone over the next two sessions. The unemployment rate for the latest period lands on 17 November, with a prior reading of 3.9%, followed by the composite CPI on 20 November, prior at 1.9%. On the company side, WuXi AppTec’s fiscal 2026 annual results are scheduled for 15 March 2027, leaving no near-term earnings catalyst. The open question is whether the market’s repricing around the 1260H removal carries into next week, and whether more brokers weigh in during the 90-day catalyst window.

In Short

The week left a clear tension. Analysts are almost uniformly constructive, with a strong-buy consensus and a target price more than 20% above spot. The 1260H removal is a concrete regulatory milestone. Yet the stock still fell 3.23% on the week and gave back its post-announcement rally, suggesting short-term money did not chase the news. The latest session showed large-lot money turning net seller, while valuation at roughly 18.7x earnings and 5.1x book is not in distressed territory. What to watch next is whether the gap between broker consensus and actual fund flows narrows, and whether order momentum or guidance firms up inside the 90-day window.

This article is generated by LongbridgeAI from market data, for information only and not investment advice.

Source: Weekly Review The copyright of this article belongs to the original author/organization.

The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.